Diabetes Obes Metab. 2012 Nov;14(11):1050-3. doi: 10.1111/j.1463-1326.2012.01629.x. Epub 2012 Jun 25.
The effects of linagliptin on fat content in diet-induced obese rats were compared with those of the appetite suppressant sibutramine. Female Wistar rats fed a high-fat diet (HFD) for 3 months received vehicle, linagliptin (10 mg/kg) or sibutramine (5 mg/kg) treatment orally, once daily for 6 additional weeks, while continuing the HFD. Magnetic resonance spectroscopy analysis of fat content was performed at baseline and at the end of the 6-week treatment period. Linagliptin treatment profoundly reduced hepatic fat compared with vehicle, with an effect comparable to that of sibutramine. The vehicle-corrected mean change (95% CI) from baseline in hepatic fat and intramyocellular lipid was -59.0% (-104.3%, -13.6%; p = 0.015) and -62.1% (-131.6%, 7.4%; p = 0.073), respectively, for linagliptin compared with -54.3% (-101.5%, -7.1%; p = 0.027) and -72.4% (-142.4%, -2.4%; p = 0.044), respectively, for sibutramine.
比较了利拉利汀对饮食诱导肥胖大鼠脂肪含量的影响与食欲抑制剂西布曲明的影响。3 个月来用高脂肪饮食喂养的雌性 Wistar 大鼠继续用高脂肪饮食喂养，同时每天口服一次给予 vehicle、利拉利汀（10mg/kg）或西布曲明（5mg/kg）治疗 6 周。在基线和 6 周治疗期结束时进行脂肪含量的磁共振波谱分析。与 vehicle 相比，利拉利汀治疗可显著降低肝脏脂肪，其效果可与西布曲明相媲美。与 vehicle 相比，利拉利汀的肝脏脂肪和肌内脂肪的校正平均变化（95%CI）分别为-59.0%（-104.3%，-13.6%；p=0.015）和-62.1%（-131.6%，7.4%；p=0.073），而西布曲明分别为-54.3%（-101.5%，-7.1%；p=0.027）和-72.4%（-142.4%，-2.4%；p=0.044）。
